Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
2.370
+0.050 (+2.16%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cellectis S.A. ADR
< Previous
1
2
3
Next >
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
August 07, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Financial Results for the Second Quarter 2024
August 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
August 01, 2024
From
Cellectis Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
June 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
June 20, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
June 12, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
June 04, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 02, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
April 29, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
April 22, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
April 10, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
November 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
November 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
October 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
October 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
August 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.